[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fppG_5vQuEqZOnsf0wJMCIZYTw-hBMMIKJSaE6Cfl1go":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":86,"rows":93},"Institut Curie",[4],134,false,40,12,39445,30,78,[14,17,20,23,26,28,30,33],{"name":15,"count":16},"Breast Cancer",18,{"name":18,"count":19},"Cancer",13,{"name":21,"count":22},"Uveal Melanoma",7,{"name":24,"count":25},"Cervical Cancer",5,{"name":27,"count":25},"Triple Negative Breast Cancer",{"name":29,"count":25},"Neuroblastoma",{"name":31,"count":32},"Surgery",4,{"name":34,"count":32},"Solid Tumor, Adult",[36,41,46,51,56,61,66,71,76,81],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT02866136","Conservative Treatments of Retinoblastoma","2023-01","VP16, carboplatin",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06175390","Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer","2026-08-15","Tumor samples analysis",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05282901","Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)","2026-10-30","Pembrolizumab 25 MG\u002F1 ML Intravenous Solution",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT04733027","First-in-human Phase I to Evaluate PEP-010 as Single Agent and in Combination With Paclitaxel or With Gemcitabine (CleverPeptide)","2026-12-30","Dose escalation, first-in-human phase I clinical trial with an Expansion phase",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT05439005","Opioid Free Versus Opioid Based Anaesthesia for Free Flap Reconstruction Surgery of the Breast: A Phase III Multicentric Randomized Controlled Study.","2027-06-06","Dexmedetomidine",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT05955170","Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer","2027-12-19","Tucatinib in Combination of Oral VP16 and trastuzumab",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT07193394","Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer","2028-12-07","Tucatinib",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT04790682","LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG","2029-06-03","assessment of the predictive value of ctDNA level of the prominent mutant allele variation between baseline and week 6, on response to treatment according to RECIST 1.1 criteria.",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT06659705","Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)","2029-08-04","68Ga-FAPI-46 for PET \u002F CT scan",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT06195709","ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients","2029-09-27","Endocrine therapy",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,121,139,157,186,204,222,240,260,298,339,357,385,403,421,439,457,479,497,524,542,560,578,596,618,636,658,680,702,729,750,777,804,822,859,881,907,931,958,986,1004,1022,1059,1097,1125,1153,1180,1198,1224,1242,1276,1294,1312,1330,1348,1366,1384,1402,1420,1438,1463,1491,1509,1527,1545,1563,1588,1613,1637,1655,1673,1698,1724,1750,1776,1794,1822,1846,1909,1932,1955,1978,1996,2023,2041,2064,2089],{"intervention":85,"totalTrials":95,"cells":96},1,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":117,"NA":119},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":95,"soonestReadout":84},[106],{"nctId":82,"briefTitle":83,"status":107,"phases":108,"primaryCompletion":84,"completion":109,"start":110,"enrollment":111,"conditions":112,"interventions":114},"RECRUITING",[90],"2030-09-27","2024-05-27",300,[113],"Breast Carcinoma",[85,115,116],"Endocrine therapy combined with the local treatment of FES-negative lesions","Chemotherapy",{"trials":118,"activeCount":99},[],{"trials":120,"activeCount":99},[],{"intervention":115,"totalTrials":95,"cells":122},{"EARLY_PHASE1":123,"PHASE1":125,"PHASE2":127,"PHASE3":129,"PHASE4":135,"NA":137},{"trials":124,"activeCount":99},[],{"trials":126,"activeCount":99},[],{"trials":128,"activeCount":99},[],{"trials":130,"activeCount":95,"soonestReadout":84},[131],{"nctId":82,"briefTitle":83,"status":107,"phases":132,"primaryCompletion":84,"completion":109,"start":110,"enrollment":111,"conditions":133,"interventions":134},[90],[113],[85,115,116],{"trials":136,"activeCount":99},[],{"trials":138,"activeCount":99},[],{"intervention":116,"totalTrials":95,"cells":140},{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":147,"PHASE4":153,"NA":155},{"trials":142,"activeCount":99},[],{"trials":144,"activeCount":99},[],{"trials":146,"activeCount":99},[],{"trials":148,"activeCount":95,"soonestReadout":84},[149],{"nctId":82,"briefTitle":83,"status":107,"phases":150,"primaryCompletion":84,"completion":109,"start":110,"enrollment":111,"conditions":151,"interventions":152},[90],[113],[85,115,116],{"trials":154,"activeCount":99},[],{"trials":156,"activeCount":99},[],{"intervention":158,"totalTrials":95,"cells":159},"Melphalan or Melphalan + Topotecan",{"EARLY_PHASE1":160,"PHASE1":162,"PHASE2":164,"PHASE3":166,"PHASE4":182,"NA":184},{"trials":161,"activeCount":99},[],{"trials":163,"activeCount":99},[],{"trials":165,"activeCount":99},[],{"trials":167,"activeCount":95,"soonestReadout":172},[168],{"nctId":169,"briefTitle":170,"status":107,"phases":171,"primaryCompletion":172,"completion":173,"start":174,"enrollment":175,"conditions":176,"interventions":178},"NCT04681417","Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome",[89,90],"2035-01-20","2036-01-20","2021-03-25",225,[177],"Retinoblastoma",[158,179,180,181],"etoposide, carboplatin and vincristine or local ophthalmological treatment without IV chemotherapy","Carboplatin administered on Day 1","Intravitreal Melphalan chemotherapy injections",{"trials":183,"activeCount":99},[],{"trials":185,"activeCount":99},[],{"intervention":179,"totalTrials":95,"cells":187},{"EARLY_PHASE1":188,"PHASE1":190,"PHASE2":192,"PHASE3":194,"PHASE4":200,"NA":202},{"trials":189,"activeCount":99},[],{"trials":191,"activeCount":99},[],{"trials":193,"activeCount":99},[],{"trials":195,"activeCount":95,"soonestReadout":172},[196],{"nctId":169,"briefTitle":170,"status":107,"phases":197,"primaryCompletion":172,"completion":173,"start":174,"enrollment":175,"conditions":198,"interventions":199},[89,90],[177],[158,179,180,181],{"trials":201,"activeCount":99},[],{"trials":203,"activeCount":99},[],{"intervention":180,"totalTrials":95,"cells":205},{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":210,"PHASE3":212,"PHASE4":218,"NA":220},{"trials":207,"activeCount":99},[],{"trials":209,"activeCount":99},[],{"trials":211,"activeCount":99},[],{"trials":213,"activeCount":95,"soonestReadout":172},[214],{"nctId":169,"briefTitle":170,"status":107,"phases":215,"primaryCompletion":172,"completion":173,"start":174,"enrollment":175,"conditions":216,"interventions":217},[89,90],[177],[158,179,180,181],{"trials":219,"activeCount":99},[],{"trials":221,"activeCount":99},[],{"intervention":181,"totalTrials":95,"cells":223},{"EARLY_PHASE1":224,"PHASE1":226,"PHASE2":228,"PHASE3":230,"PHASE4":236,"NA":238},{"trials":225,"activeCount":99},[],{"trials":227,"activeCount":99},[],{"trials":229,"activeCount":99},[],{"trials":231,"activeCount":95,"soonestReadout":172},[232],{"nctId":169,"briefTitle":170,"status":107,"phases":233,"primaryCompletion":172,"completion":173,"start":174,"enrollment":175,"conditions":234,"interventions":235},[89,90],[177],[158,179,180,181],{"trials":237,"activeCount":99},[],{"trials":239,"activeCount":99},[],{"intervention":60,"totalTrials":95,"cells":241},{"EARLY_PHASE1":242,"PHASE1":244,"PHASE2":246,"PHASE3":248,"PHASE4":256,"NA":258},{"trials":243,"activeCount":99},[],{"trials":245,"activeCount":99},[],{"trials":247,"activeCount":99},[],{"trials":249,"activeCount":95,"soonestReadout":59},[250],{"nctId":57,"briefTitle":58,"status":107,"phases":251,"primaryCompletion":59,"completion":59,"start":252,"enrollment":253,"conditions":254,"interventions":255},[90],"2022-12-07",158,[15],[60],{"trials":257,"activeCount":99},[],{"trials":259,"activeCount":99},[],{"intervention":261,"totalTrials":262,"cells":263},"Trastuzumab",2,{"EARLY_PHASE1":264,"PHASE1":266,"PHASE2":268,"PHASE3":292,"PHASE4":294,"NA":296},{"trials":265,"activeCount":99},[],{"trials":267,"activeCount":99},[],{"trials":269,"activeCount":95,"soonestReadout":69},[270,279],{"nctId":67,"briefTitle":68,"status":107,"phases":271,"primaryCompletion":69,"completion":272,"start":273,"enrollment":274,"conditions":275,"interventions":278},[89],"2029-06-08","2026-01-31",20,[276,277],"Metastatic Breast Cancer ( HER2 Negative)","Unresectable Breast Cancer",[70,261],{"nctId":280,"briefTitle":281,"status":282,"phases":283,"primaryCompletion":284,"completion":285,"start":286,"enrollment":287,"conditions":288,"interventions":291},"NCT01373710","Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis","COMPLETED",[88,89],"2018-04","2018-04-09","2011-05-19",34,[289,290],"Metastatic Breast Cancer","Carcinomatous Meningitis",[261],{"trials":293,"activeCount":99},[],{"trials":295,"activeCount":99},[],{"trials":297,"activeCount":99},[],{"intervention":299,"totalTrials":262,"cells":300},"Lenalidomide",{"EARLY_PHASE1":301,"PHASE1":303,"PHASE2":305,"PHASE3":333,"PHASE4":335,"NA":337},{"trials":302,"activeCount":99},[],{"trials":304,"activeCount":99},[],{"trials":306,"activeCount":95,"soonestReadout":312},[307,321],{"nctId":308,"briefTitle":309,"status":310,"phases":311,"primaryCompletion":312,"completion":313,"start":314,"enrollment":315,"conditions":316,"interventions":319},"NCT04446962","LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)","ACTIVE_NOT_RECRUITING",[88,89],"2035-02-02","2035-08-30","2020-10-30",118,[317,318],"Lymphoma, Large B-Cell, Diffuse","Central Nervous System Neoplasms, Primary",[299,320],"Ibrutinib",{"nctId":322,"briefTitle":323,"status":282,"phases":324,"primaryCompletion":325,"completion":325,"start":326,"enrollment":327,"conditions":328,"interventions":331},"NCT01956695","Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma",[89],"2018-01-11","2013-09-18",45,[329,330],"Lymphoma","Relapse",[299,332],"Rituximab",{"trials":334,"activeCount":99},[],{"trials":336,"activeCount":99},[],{"trials":338,"activeCount":99},[],{"intervention":70,"totalTrials":95,"cells":340},{"EARLY_PHASE1":341,"PHASE1":343,"PHASE2":345,"PHASE3":351,"PHASE4":353,"NA":355},{"trials":342,"activeCount":99},[],{"trials":344,"activeCount":99},[],{"trials":346,"activeCount":95,"soonestReadout":69},[347],{"nctId":67,"briefTitle":68,"status":107,"phases":348,"primaryCompletion":69,"completion":272,"start":273,"enrollment":274,"conditions":349,"interventions":350},[89],[276,277],[70,261],{"trials":352,"activeCount":99},[],{"trials":354,"activeCount":99},[],{"trials":356,"activeCount":99},[],{"intervention":358,"totalTrials":95,"cells":359},"Etoposide",{"EARLY_PHASE1":360,"PHASE1":362,"PHASE2":364,"PHASE3":379,"PHASE4":381,"NA":383},{"trials":361,"activeCount":99},[],{"trials":363,"activeCount":99},[],{"trials":365,"activeCount":95,"soonestReadout":370},[366],{"nctId":367,"briefTitle":368,"status":310,"phases":369,"primaryCompletion":370,"completion":370,"start":371,"enrollment":372,"conditions":373,"interventions":374},"NCT02870907","Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)",[89],"2031-03-01","2010-03-18",195,[177],[358,375,376,375,377,376,358,376,378,375,377,376,358,378],"Vincristine","Carboplatin","Cyclophosphamide","Thiotepa",{"trials":380,"activeCount":99},[],{"trials":382,"activeCount":99},[],{"trials":384,"activeCount":99},[],{"intervention":375,"totalTrials":95,"cells":386},{"EARLY_PHASE1":387,"PHASE1":389,"PHASE2":391,"PHASE3":397,"PHASE4":399,"NA":401},{"trials":388,"activeCount":99},[],{"trials":390,"activeCount":99},[],{"trials":392,"activeCount":95,"soonestReadout":370},[393],{"nctId":367,"briefTitle":368,"status":310,"phases":394,"primaryCompletion":370,"completion":370,"start":371,"enrollment":372,"conditions":395,"interventions":396},[89],[177],[358,375,376,375,377,376,358,376,378,375,377,376,358,378],{"trials":398,"activeCount":99},[],{"trials":400,"activeCount":99},[],{"trials":402,"activeCount":99},[],{"intervention":376,"totalTrials":95,"cells":404},{"EARLY_PHASE1":405,"PHASE1":407,"PHASE2":409,"PHASE3":415,"PHASE4":417,"NA":419},{"trials":406,"activeCount":99},[],{"trials":408,"activeCount":99},[],{"trials":410,"activeCount":95,"soonestReadout":370},[411],{"nctId":367,"briefTitle":368,"status":310,"phases":412,"primaryCompletion":370,"completion":370,"start":371,"enrollment":372,"conditions":413,"interventions":414},[89],[177],[358,375,376,375,377,376,358,376,378,375,377,376,358,378],{"trials":416,"activeCount":99},[],{"trials":418,"activeCount":99},[],{"trials":420,"activeCount":99},[],{"intervention":377,"totalTrials":95,"cells":422},{"EARLY_PHASE1":423,"PHASE1":425,"PHASE2":427,"PHASE3":433,"PHASE4":435,"NA":437},{"trials":424,"activeCount":99},[],{"trials":426,"activeCount":99},[],{"trials":428,"activeCount":95,"soonestReadout":370},[429],{"nctId":367,"briefTitle":368,"status":310,"phases":430,"primaryCompletion":370,"completion":370,"start":371,"enrollment":372,"conditions":431,"interventions":432},[89],[177],[358,375,376,375,377,376,358,376,378,375,377,376,358,378],{"trials":434,"activeCount":99},[],{"trials":436,"activeCount":99},[],{"trials":438,"activeCount":99},[],{"intervention":378,"totalTrials":95,"cells":440},{"EARLY_PHASE1":441,"PHASE1":443,"PHASE2":445,"PHASE3":451,"PHASE4":453,"NA":455},{"trials":442,"activeCount":99},[],{"trials":444,"activeCount":99},[],{"trials":446,"activeCount":95,"soonestReadout":370},[447],{"nctId":367,"briefTitle":368,"status":310,"phases":448,"primaryCompletion":370,"completion":370,"start":371,"enrollment":372,"conditions":449,"interventions":450},[89],[177],[358,375,376,375,377,376,358,376,378,375,377,376,358,378],{"trials":452,"activeCount":99},[],{"trials":454,"activeCount":99},[],{"trials":456,"activeCount":99},[],{"intervention":45,"totalTrials":95,"cells":458},{"EARLY_PHASE1":459,"PHASE1":461,"PHASE2":463,"PHASE3":473,"PHASE4":475,"NA":477},{"trials":460,"activeCount":99},[],{"trials":462,"activeCount":99},[],{"trials":464,"activeCount":95,"soonestReadout":44},[465],{"nctId":42,"briefTitle":43,"status":310,"phases":466,"primaryCompletion":44,"completion":467,"start":468,"enrollment":469,"conditions":470,"interventions":471},[89],"2029-02-15","2024-03-27",81,[27],[45,472],"Blood samples analysis: Circulating Tumor DNA",{"trials":474,"activeCount":99},[],{"trials":476,"activeCount":99},[],{"trials":478,"activeCount":99},[],{"intervention":472,"totalTrials":95,"cells":480},{"EARLY_PHASE1":481,"PHASE1":483,"PHASE2":485,"PHASE3":491,"PHASE4":493,"NA":495},{"trials":482,"activeCount":99},[],{"trials":484,"activeCount":99},[],{"trials":486,"activeCount":95,"soonestReadout":44},[487],{"nctId":42,"briefTitle":43,"status":310,"phases":488,"primaryCompletion":44,"completion":467,"start":468,"enrollment":469,"conditions":489,"interventions":490},[89],[27],[45,472],{"trials":492,"activeCount":99},[],{"trials":494,"activeCount":99},[],{"trials":496,"activeCount":99},[],{"intervention":40,"totalTrials":95,"cells":498},{"EARLY_PHASE1":499,"PHASE1":501,"PHASE2":503,"PHASE3":518,"PHASE4":520,"NA":522},{"trials":500,"activeCount":99},[],{"trials":502,"activeCount":99},[],{"trials":504,"activeCount":95,"soonestReadout":39},[505],{"nctId":37,"briefTitle":38,"status":310,"phases":506,"primaryCompletion":39,"completion":507,"start":508,"enrollment":509,"conditions":510,"interventions":513},[89],"2035-09","2012-02",133,[177,511,512],"Children","Retinal Neoplasm",[40,514,515,516,517],"Melphalan","VP16, carboplatin, vincristin","Carboplatin + laser day 1","intravitreal Melphalan",{"trials":519,"activeCount":99},[],{"trials":521,"activeCount":99},[],{"trials":523,"activeCount":99},[],{"intervention":514,"totalTrials":95,"cells":525},{"EARLY_PHASE1":526,"PHASE1":528,"PHASE2":530,"PHASE3":536,"PHASE4":538,"NA":540},{"trials":527,"activeCount":99},[],{"trials":529,"activeCount":99},[],{"trials":531,"activeCount":95,"soonestReadout":39},[532],{"nctId":37,"briefTitle":38,"status":310,"phases":533,"primaryCompletion":39,"completion":507,"start":508,"enrollment":509,"conditions":534,"interventions":535},[89],[177,511,512],[40,514,515,516,517],{"trials":537,"activeCount":99},[],{"trials":539,"activeCount":99},[],{"trials":541,"activeCount":99},[],{"intervention":515,"totalTrials":95,"cells":543},{"EARLY_PHASE1":544,"PHASE1":546,"PHASE2":548,"PHASE3":554,"PHASE4":556,"NA":558},{"trials":545,"activeCount":99},[],{"trials":547,"activeCount":99},[],{"trials":549,"activeCount":95,"soonestReadout":39},[550],{"nctId":37,"briefTitle":38,"status":310,"phases":551,"primaryCompletion":39,"completion":507,"start":508,"enrollment":509,"conditions":552,"interventions":553},[89],[177,511,512],[40,514,515,516,517],{"trials":555,"activeCount":99},[],{"trials":557,"activeCount":99},[],{"trials":559,"activeCount":99},[],{"intervention":516,"totalTrials":95,"cells":561},{"EARLY_PHASE1":562,"PHASE1":564,"PHASE2":566,"PHASE3":572,"PHASE4":574,"NA":576},{"trials":563,"activeCount":99},[],{"trials":565,"activeCount":99},[],{"trials":567,"activeCount":95,"soonestReadout":39},[568],{"nctId":37,"briefTitle":38,"status":310,"phases":569,"primaryCompletion":39,"completion":507,"start":508,"enrollment":509,"conditions":570,"interventions":571},[89],[177,511,512],[40,514,515,516,517],{"trials":573,"activeCount":99},[],{"trials":575,"activeCount":99},[],{"trials":577,"activeCount":99},[],{"intervention":517,"totalTrials":95,"cells":579},{"EARLY_PHASE1":580,"PHASE1":582,"PHASE2":584,"PHASE3":590,"PHASE4":592,"NA":594},{"trials":581,"activeCount":99},[],{"trials":583,"activeCount":99},[],{"trials":585,"activeCount":95,"soonestReadout":39},[586],{"nctId":37,"briefTitle":38,"status":310,"phases":587,"primaryCompletion":39,"completion":507,"start":508,"enrollment":509,"conditions":588,"interventions":589},[89],[177,511,512],[40,514,515,516,517],{"trials":591,"activeCount":99},[],{"trials":593,"activeCount":99},[],{"trials":595,"activeCount":99},[],{"intervention":65,"totalTrials":95,"cells":597},{"EARLY_PHASE1":598,"PHASE1":600,"PHASE2":602,"PHASE3":612,"PHASE4":614,"NA":616},{"trials":599,"activeCount":99},[],{"trials":601,"activeCount":99},[],{"trials":603,"activeCount":95,"soonestReadout":64},[604],{"nctId":62,"briefTitle":63,"status":107,"phases":605,"primaryCompletion":64,"completion":606,"start":607,"enrollment":608,"conditions":609,"interventions":611},[89],"2028-12-19","2023-12-19",66,[610],"HER2-positive Breast Cancer",[65],{"trials":613,"activeCount":99},[],{"trials":615,"activeCount":99},[],{"trials":617,"activeCount":99},[],{"intervention":320,"totalTrials":95,"cells":619},{"EARLY_PHASE1":620,"PHASE1":622,"PHASE2":624,"PHASE3":630,"PHASE4":632,"NA":634},{"trials":621,"activeCount":99},[],{"trials":623,"activeCount":99},[],{"trials":625,"activeCount":95,"soonestReadout":312},[626],{"nctId":308,"briefTitle":309,"status":310,"phases":627,"primaryCompletion":312,"completion":313,"start":314,"enrollment":315,"conditions":628,"interventions":629},[88,89],[317,318],[299,320],{"trials":631,"activeCount":99},[],{"trials":633,"activeCount":99},[],{"trials":635,"activeCount":99},[],{"intervention":50,"totalTrials":95,"cells":637},{"EARLY_PHASE1":638,"PHASE1":640,"PHASE2":642,"PHASE3":652,"PHASE4":654,"NA":656},{"trials":639,"activeCount":99},[],{"trials":641,"activeCount":99},[],{"trials":643,"activeCount":95,"soonestReadout":49},[644],{"nctId":47,"briefTitle":48,"status":310,"phases":645,"primaryCompletion":49,"completion":646,"start":647,"enrollment":648,"conditions":649,"interventions":651},[89],"2026-11-15","2022-07-07",51,[650],"Metastatic Uveal Melanoma",[50],{"trials":653,"activeCount":99},[],{"trials":655,"activeCount":99},[],{"trials":657,"activeCount":99},[],{"intervention":80,"totalTrials":95,"cells":659},{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":674,"PHASE4":676,"NA":678},{"trials":661,"activeCount":99},[],{"trials":663,"activeCount":99},[],{"trials":665,"activeCount":95,"soonestReadout":79},[666],{"nctId":77,"briefTitle":78,"status":107,"phases":667,"primaryCompletion":79,"completion":668,"start":669,"enrollment":670,"conditions":671,"interventions":673},[89],"2030-08-08","2025-12-02",35,[672],"Pancreatic Ductal Adenocarcinoma (PDAC)",[80],{"trials":675,"activeCount":99},[],{"trials":677,"activeCount":99},[],{"trials":679,"activeCount":99},[],{"intervention":55,"totalTrials":95,"cells":681},{"EARLY_PHASE1":682,"PHASE1":692,"PHASE2":694,"PHASE3":696,"PHASE4":698,"NA":700},{"trials":683,"activeCount":95,"soonestReadout":54},[684],{"nctId":52,"briefTitle":53,"status":310,"phases":685,"primaryCompletion":54,"completion":686,"start":687,"enrollment":688,"conditions":689,"interventions":691},[87],"2027-01-31","2021-05-18",57,[690],"Metastatic Solid Tumor Cancer",[55],{"trials":693,"activeCount":99},[],{"trials":695,"activeCount":99},[],{"trials":697,"activeCount":99},[],{"trials":699,"activeCount":99},[],{"trials":701,"activeCount":99},[],{"intervention":703,"totalTrials":95,"cells":704},"salivary kit",{"EARLY_PHASE1":705,"PHASE1":707,"PHASE2":709,"PHASE3":711,"PHASE4":713,"NA":715},{"trials":706,"activeCount":99},[],{"trials":708,"activeCount":99},[],{"trials":710,"activeCount":99},[],{"trials":712,"activeCount":99},[],{"trials":714,"activeCount":99},[],{"trials":716,"activeCount":95,"soonestReadout":721},[717],{"nctId":718,"briefTitle":719,"status":107,"phases":720,"primaryCompletion":721,"completion":722,"start":723,"enrollment":724,"conditions":725,"interventions":728},"NCT01689584","COsegregation of VARiants in Panel of Genes",[92],"2037-07-02","2038-01-02","2012-07-02",11000,[726,727],"Gene Mutation-Related Cancer","Genetic Predisposition",[703],{"intervention":75,"totalTrials":95,"cells":730},{"EARLY_PHASE1":731,"PHASE1":733,"PHASE2":735,"PHASE3":737,"PHASE4":739,"NA":741},{"trials":732,"activeCount":99},[],{"trials":734,"activeCount":99},[],{"trials":736,"activeCount":99},[],{"trials":738,"activeCount":99},[],{"trials":740,"activeCount":99},[],{"trials":742,"activeCount":95,"soonestReadout":74},[743],{"nctId":72,"briefTitle":73,"status":107,"phases":744,"primaryCompletion":74,"completion":745,"start":746,"enrollment":111,"conditions":747,"interventions":749},[92],"2030-06-03","2021-05-22",[748],"Metastatic Lung Cancer",[75],{"intervention":751,"totalTrials":95,"cells":752},"Chlorhydrate de Ropivacaine",{"EARLY_PHASE1":753,"PHASE1":755,"PHASE2":757,"PHASE3":759,"PHASE4":761,"NA":775},{"trials":754,"activeCount":99},[],{"trials":756,"activeCount":99},[],{"trials":758,"activeCount":99},[],{"trials":760,"activeCount":99},[],{"trials":762,"activeCount":99},[763],{"nctId":764,"briefTitle":765,"status":282,"phases":766,"primaryCompletion":767,"completion":768,"start":769,"enrollment":770,"conditions":771,"interventions":774},"NCT00370240","Chlorhydrate of Ropivacaine and Breast Cancer Surgery",[91],"2007-07","2008-11","2006-09",260,[772,773],"Breast Neoplasms","Pain,Postoperative",[751],{"trials":776,"activeCount":99},[],{"intervention":778,"totalTrials":95,"cells":779},"Ropivacaïne Hydrochloride by Erector Spinae block",{"EARLY_PHASE1":780,"PHASE1":782,"PHASE2":784,"PHASE3":786,"PHASE4":788,"NA":802},{"trials":781,"activeCount":99},[],{"trials":783,"activeCount":99},[],{"trials":785,"activeCount":99},[],{"trials":787,"activeCount":99},[],{"trials":789,"activeCount":99},[790],{"nctId":791,"briefTitle":792,"status":282,"phases":793,"primaryCompletion":794,"completion":795,"start":796,"enrollment":797,"conditions":798,"interventions":800},"NCT04827030","ER-One: A Double-blind Trial of Erector Spinae Block (ESP) Versus Paravertebral Block (PVB) Before Breast Cancer Surgery",[91],"2023-06-14","2023-07-14","2021-06-28",292,[799],"Breast Surgery",[778,801],"Ropivacaïne Hydrochloride by Paravertebral block",{"trials":803,"activeCount":99},[],{"intervention":801,"totalTrials":95,"cells":805},{"EARLY_PHASE1":806,"PHASE1":808,"PHASE2":810,"PHASE3":812,"PHASE4":814,"NA":820},{"trials":807,"activeCount":99},[],{"trials":809,"activeCount":99},[],{"trials":811,"activeCount":99},[],{"trials":813,"activeCount":99},[],{"trials":815,"activeCount":99},[816],{"nctId":791,"briefTitle":792,"status":282,"phases":817,"primaryCompletion":794,"completion":795,"start":796,"enrollment":797,"conditions":818,"interventions":819},[91],[799],[778,801],{"trials":821,"activeCount":99},[],{"intervention":823,"totalTrials":262,"cells":824},"Saline",{"EARLY_PHASE1":825,"PHASE1":827,"PHASE2":829,"PHASE3":831,"PHASE4":855,"NA":857},{"trials":826,"activeCount":99},[],{"trials":828,"activeCount":99},[],{"trials":830,"activeCount":99},[],{"trials":832,"activeCount":99},[833,845],{"nctId":834,"briefTitle":835,"status":282,"phases":836,"primaryCompletion":837,"completion":838,"start":839,"enrollment":840,"conditions":841,"interventions":843},"NCT04327063","MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer Surgery",[90],"2021-12-30","2022-01-28","2020-08-04",182,[842],"Malignant Neoplasm of Breast",[823,844],"Ropivacaine",{"nctId":846,"briefTitle":847,"status":282,"phases":848,"primaryCompletion":849,"completion":850,"start":851,"enrollment":852,"conditions":853,"interventions":854},"NCT02408393","MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery",[90],"2018-07","2019-03-09","2015-03-27",380,[842],[823,844],{"trials":856,"activeCount":99},[],{"trials":858,"activeCount":99},[],{"intervention":844,"totalTrials":262,"cells":860},{"EARLY_PHASE1":861,"PHASE1":863,"PHASE2":865,"PHASE3":867,"PHASE4":877,"NA":879},{"trials":862,"activeCount":99},[],{"trials":864,"activeCount":99},[],{"trials":866,"activeCount":99},[],{"trials":868,"activeCount":99},[869,873],{"nctId":834,"briefTitle":835,"status":282,"phases":870,"primaryCompletion":837,"completion":838,"start":839,"enrollment":840,"conditions":871,"interventions":872},[90],[842],[823,844],{"nctId":846,"briefTitle":847,"status":282,"phases":874,"primaryCompletion":849,"completion":850,"start":851,"enrollment":852,"conditions":875,"interventions":876},[90],[842],[823,844],{"trials":878,"activeCount":99},[],{"trials":880,"activeCount":99},[],{"intervention":882,"totalTrials":95,"cells":883},"Circulating tumor cells counting at baseline",{"EARLY_PHASE1":884,"PHASE1":886,"PHASE2":888,"PHASE3":890,"PHASE4":903,"NA":905},{"trials":885,"activeCount":99},[],{"trials":887,"activeCount":99},[],{"trials":889,"activeCount":99},[],{"trials":891,"activeCount":99},[892],{"nctId":893,"briefTitle":894,"status":895,"phases":896,"primaryCompletion":897,"completion":897,"start":508,"enrollment":898,"conditions":899,"interventions":902},"NCT01710605","Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers","UNKNOWN",[90],"2018-09",800,[900,901],"Ductal Infiltrating Metastatic Breast Cancer","Hormone-receptors Positive Breast Cancer",[882],{"trials":904,"activeCount":99},[],{"trials":906,"activeCount":99},[],{"intervention":908,"totalTrials":95,"cells":909},"Adjuvant chemotherapy by Fotemustin",{"EARLY_PHASE1":910,"PHASE1":912,"PHASE2":914,"PHASE3":916,"PHASE4":927,"NA":929},{"trials":911,"activeCount":99},[],{"trials":913,"activeCount":99},[],{"trials":915,"activeCount":99},[],{"trials":917,"activeCount":99},[918],{"nctId":919,"briefTitle":920,"status":282,"phases":921,"primaryCompletion":922,"completion":922,"start":923,"enrollment":924,"conditions":925,"interventions":926},"NCT02843386","Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma",[90],"2020-06-12","2009-06-23",302,[21],[908],{"trials":928,"activeCount":99},[],{"trials":930,"activeCount":99},[],{"intervention":932,"totalTrials":95,"cells":933},"Morphine gel",{"EARLY_PHASE1":934,"PHASE1":936,"PHASE2":938,"PHASE3":940,"PHASE4":954,"NA":956},{"trials":935,"activeCount":99},[],{"trials":937,"activeCount":99},[],{"trials":939,"activeCount":99},[],{"trials":941,"activeCount":99},[942],{"nctId":943,"briefTitle":944,"status":945,"phases":946,"primaryCompletion":947,"completion":947,"start":948,"enrollment":949,"conditions":950,"interventions":953},"NCT02028923","Efficacy of Topical Morphine in the Treatment of Severe Local Pain of Chronic Wounds","TERMINATED",[90],"2016-07","2014-04",126,[951,952],"Local Pain","Chronic Wounds",[932],{"trials":955,"activeCount":99},[],{"trials":957,"activeCount":99},[],{"intervention":959,"totalTrials":95,"cells":960},"Dexamethasone acetate",{"EARLY_PHASE1":961,"PHASE1":963,"PHASE2":965,"PHASE3":967,"PHASE4":982,"NA":984},{"trials":962,"activeCount":99},[],{"trials":964,"activeCount":99},[],{"trials":966,"activeCount":99},[],{"trials":968,"activeCount":99},[969],{"nctId":970,"briefTitle":971,"status":282,"phases":972,"primaryCompletion":973,"completion":974,"start":975,"enrollment":976,"conditions":977,"interventions":979},"NCT01868269","Opsoclonus Myoclonus Syndrome\u002FDancing Eye Syndrome (OMS\u002FDES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome\u002FDancing Eye Syndrome (OMS\u002FDES) in Children With and Without Neuroblastoma (NBpos and NBneg)",[90],"2021-05-09","2025-01-17","2013-04-18",102,[978,29],"Opsoclonus Myoclonus Syndrome",[959,980,981],"dexamethasone and cyclophosphamide","dexamethasone and rituximab",{"trials":983,"activeCount":99},[],{"trials":985,"activeCount":99},[],{"intervention":980,"totalTrials":95,"cells":987},{"EARLY_PHASE1":988,"PHASE1":990,"PHASE2":992,"PHASE3":994,"PHASE4":1000,"NA":1002},{"trials":989,"activeCount":99},[],{"trials":991,"activeCount":99},[],{"trials":993,"activeCount":99},[],{"trials":995,"activeCount":99},[996],{"nctId":970,"briefTitle":971,"status":282,"phases":997,"primaryCompletion":973,"completion":974,"start":975,"enrollment":976,"conditions":998,"interventions":999},[90],[978,29],[959,980,981],{"trials":1001,"activeCount":99},[],{"trials":1003,"activeCount":99},[],{"intervention":981,"totalTrials":95,"cells":1005},{"EARLY_PHASE1":1006,"PHASE1":1008,"PHASE2":1010,"PHASE3":1012,"PHASE4":1018,"NA":1020},{"trials":1007,"activeCount":99},[],{"trials":1009,"activeCount":99},[],{"trials":1011,"activeCount":99},[],{"trials":1013,"activeCount":99},[1014],{"nctId":970,"briefTitle":971,"status":282,"phases":1015,"primaryCompletion":973,"completion":974,"start":975,"enrollment":976,"conditions":1016,"interventions":1017},[90],[978,29],[959,980,981],{"trials":1019,"activeCount":99},[],{"trials":1021,"activeCount":99},[],{"intervention":1023,"totalTrials":262,"cells":1024},"Bevacizumab",{"EARLY_PHASE1":1025,"PHASE1":1027,"PHASE2":1039,"PHASE3":1053,"PHASE4":1055,"NA":1057},{"trials":1026,"activeCount":99},[],{"trials":1028,"activeCount":99},[1029],{"nctId":1030,"briefTitle":1031,"status":945,"phases":1032,"primaryCompletion":1033,"completion":1034,"start":1035,"enrollment":95,"conditions":1036,"interventions":1038},"NCT02250118","Intrapleural Bevacizumab After Pleural Drainage in the Context of Breast Cancer",[88],"2017-04-12","2017-10-17","2014-12-09",[1037,15],"Pleural Effusion, Malignant",[1023],{"trials":1040,"activeCount":99},[1041],{"nctId":1042,"briefTitle":1043,"status":895,"phases":1044,"primaryCompletion":1045,"start":1046,"enrollment":670,"conditions":1047,"interventions":1049},"NCT01217398","Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye",[89],"2012-10","2009-10",[1048],"Intraocular Melanoma",[1050,1051,1052],"bevacizumab","temozolomide","polymorphism analysis",{"trials":1054,"activeCount":99},[],{"trials":1056,"activeCount":99},[],{"trials":1058,"activeCount":99},[],{"intervention":1060,"totalTrials":262,"cells":1061},"Cisplatin",{"EARLY_PHASE1":1062,"PHASE1":1064,"PHASE2":1066,"PHASE3":1091,"PHASE4":1093,"NA":1095},{"trials":1063,"activeCount":99},[],{"trials":1065,"activeCount":99},[],{"trials":1067,"activeCount":99},[1068,1079],{"nctId":1069,"briefTitle":1070,"status":282,"phases":1071,"primaryCompletion":314,"completion":1072,"start":1073,"enrollment":1074,"conditions":1075,"interventions":1077},"NCT03298893","Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months (NiCOL)",[88,89],"2022-03-07","2017-11-27",21,[24,1076],"Locally Advanced Cervical Cancer",[1078,1060],"Nivolumab",{"nctId":1080,"briefTitle":1081,"status":282,"phases":1082,"primaryCompletion":1083,"completion":1084,"start":1085,"enrollment":1086,"conditions":1087,"interventions":1088},"NCT00957411","Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage IB, Stage II, or Stage IIIB Cervical Cancer",[89],"2013-11","2014-10","2009-03",76,[24],[1089,1090],"cetuximab","cisplatin",{"trials":1092,"activeCount":99},[],{"trials":1094,"activeCount":99},[],{"trials":1096,"activeCount":99},[],{"intervention":1051,"totalTrials":262,"cells":1098},{"EARLY_PHASE1":1099,"PHASE1":1101,"PHASE2":1103,"PHASE3":1119,"PHASE4":1121,"NA":1123},{"trials":1100,"activeCount":99},[],{"trials":1102,"activeCount":99},[],{"trials":1104,"activeCount":99},[1105,1115],{"nctId":1106,"briefTitle":1107,"status":895,"phases":1108,"primaryCompletion":1109,"start":1110,"enrollment":1111,"conditions":1112,"interventions":1114},"NCT00875355","Radiation Therapy With or Without Temozolomide in Treating Women With Brain Metastases and Breast Cancer",[89],"2009-11","2007-11",100,[15,1113],"Metastatic Cancer",[1051],{"nctId":1042,"briefTitle":1043,"status":895,"phases":1116,"primaryCompletion":1045,"start":1046,"enrollment":670,"conditions":1117,"interventions":1118},[89],[1048],[1050,1051,1052],{"trials":1120,"activeCount":99},[],{"trials":1122,"activeCount":99},[],{"trials":1124,"activeCount":99},[],{"intervention":1126,"totalTrials":95,"cells":1127},"PF-05212384",{"EARLY_PHASE1":1128,"PHASE1":1130,"PHASE2":1132,"PHASE3":1147,"PHASE4":1149,"NA":1151},{"trials":1129,"activeCount":99},[],{"trials":1131,"activeCount":99},[],{"trials":1133,"activeCount":99},[1134],{"nctId":1135,"briefTitle":1136,"status":945,"phases":1137,"primaryCompletion":1138,"completion":1139,"start":1140,"enrollment":1141,"conditions":1142,"interventions":1146},"NCT02438761","PF-05212384 (PKI-587) for t-AML\u002FMDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)",[89],"2017-05-10","2018-04-23","2015-08-31",10,[1143,1144,1145],"Therapy-related Acute Myeloid Leukemia and Myelodysplastic Syndrome","Acute Myeloid Leukemia, in Relapse","de Novo Acute Myeloid Leukemia at Diagnostic",[1126],{"trials":1148,"activeCount":99},[],{"trials":1150,"activeCount":99},[],{"trials":1152,"activeCount":99},[],{"intervention":1154,"totalTrials":95,"cells":1155},"intensive chemotherapy and hematopoietic stem cell rescue",{"EARLY_PHASE1":1156,"PHASE1":1158,"PHASE2":1160,"PHASE3":1174,"PHASE4":1176,"NA":1178},{"trials":1157,"activeCount":99},[],{"trials":1159,"activeCount":99},[],{"trials":1161,"activeCount":99},[1162],{"nctId":1163,"briefTitle":1164,"status":895,"phases":1165,"primaryCompletion":1166,"completion":1167,"start":1168,"enrollment":1169,"conditions":1170,"interventions":1172},"NCT00863460","Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients",[89],"2016-05-17","2026-05","2008-10-03",140,[1171],"Primary Central Nervous System Lymphoma",[1154,1173],"MTX based chemotherapy",{"trials":1175,"activeCount":99},[],{"trials":1177,"activeCount":99},[],{"trials":1179,"activeCount":99},[],{"intervention":1173,"totalTrials":95,"cells":1181},{"EARLY_PHASE1":1182,"PHASE1":1184,"PHASE2":1186,"PHASE3":1192,"PHASE4":1194,"NA":1196},{"trials":1183,"activeCount":99},[],{"trials":1185,"activeCount":99},[],{"trials":1187,"activeCount":99},[1188],{"nctId":1163,"briefTitle":1164,"status":895,"phases":1189,"primaryCompletion":1166,"completion":1167,"start":1168,"enrollment":1169,"conditions":1190,"interventions":1191},[89],[1171],[1154,1173],{"trials":1193,"activeCount":99},[],{"trials":1195,"activeCount":99},[],{"trials":1197,"activeCount":99},[],{"intervention":1199,"totalTrials":95,"cells":1200},"18F FAZA",{"EARLY_PHASE1":1201,"PHASE1":1203,"PHASE2":1205,"PHASE3":1218,"PHASE4":1220,"NA":1222},{"trials":1202,"activeCount":99},[],{"trials":1204,"activeCount":99},[],{"trials":1206,"activeCount":99},[1207],{"nctId":1208,"briefTitle":1209,"status":282,"phases":1210,"primaryCompletion":1211,"completion":1211,"start":1212,"enrollment":1213,"conditions":1214,"interventions":1217},"NCT02802969","Improvement of Local Control in Skull Base, Spine and Sacral Chordomas Treated by Surgery and Protontherapy Targeting Hypoxic Cells Revealed by [18F]FAZA) PET\u002FCT Tracers",[89],"2024-11-28","2016-07-22",64,[1215,1216],"Skull Base Chordoma","Vertebral Chordoma",[1199],{"trials":1219,"activeCount":99},[],{"trials":1221,"activeCount":99},[],{"trials":1223,"activeCount":99},[],{"intervention":1078,"totalTrials":95,"cells":1225},{"EARLY_PHASE1":1226,"PHASE1":1228,"PHASE2":1230,"PHASE3":1236,"PHASE4":1238,"NA":1240},{"trials":1227,"activeCount":99},[],{"trials":1229,"activeCount":99},[],{"trials":1231,"activeCount":99},[1232],{"nctId":1069,"briefTitle":1070,"status":282,"phases":1233,"primaryCompletion":314,"completion":1072,"start":1073,"enrollment":1074,"conditions":1234,"interventions":1235},[88,89],[24,1076],[1078,1060],{"trials":1237,"activeCount":99},[],{"trials":1239,"activeCount":99},[],{"trials":1241,"activeCount":99},[],{"intervention":1243,"totalTrials":95,"cells":1244},"Targeted therapy based on molecular profiling : Imatinib",{"EARLY_PHASE1":1245,"PHASE1":1247,"PHASE2":1249,"PHASE3":1270,"PHASE4":1272,"NA":1274},{"trials":1246,"activeCount":99},[],{"trials":1248,"activeCount":99},[],{"trials":1250,"activeCount":99},[1251],{"nctId":1252,"briefTitle":1253,"status":282,"phases":1254,"primaryCompletion":1255,"completion":1256,"start":1045,"enrollment":1257,"conditions":1258,"interventions":1260},"NCT01771458","A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer",[89],"2016-10","2016-12",742,[1259],"Reccurent\u002FMetastatic Solid Tumor Disease",[1243,1261,1262,1263,1264,1265,1266,1267,1268,1269],"Standard Chemotherapy","Targeted therapy based on molecular profiling : Everolimus","Targeted therapy based on molecular profiling : Vemurafenib","Targeted therapy based on molecular profiling : Sorafenib","Targeted therapy based on molecular profiling : Erlotinib","Targeted therapy based on molecular profiling : Lapatinib + Trastuzumab","Targeted therapy based on molecular profiling : Dasatinib","Targeted therapy based on molecular profiling : Tamoxifen","Targeted therapy based on molecular profiling : Abiraterone",{"trials":1271,"activeCount":99},[],{"trials":1273,"activeCount":99},[],{"trials":1275,"activeCount":99},[],{"intervention":1261,"totalTrials":95,"cells":1277},{"EARLY_PHASE1":1278,"PHASE1":1280,"PHASE2":1282,"PHASE3":1288,"PHASE4":1290,"NA":1292},{"trials":1279,"activeCount":99},[],{"trials":1281,"activeCount":99},[],{"trials":1283,"activeCount":99},[1284],{"nctId":1252,"briefTitle":1253,"status":282,"phases":1285,"primaryCompletion":1255,"completion":1256,"start":1045,"enrollment":1257,"conditions":1286,"interventions":1287},[89],[1259],[1243,1261,1262,1263,1264,1265,1266,1267,1268,1269],{"trials":1289,"activeCount":99},[],{"trials":1291,"activeCount":99},[],{"trials":1293,"activeCount":99},[],{"intervention":1262,"totalTrials":95,"cells":1295},{"EARLY_PHASE1":1296,"PHASE1":1298,"PHASE2":1300,"PHASE3":1306,"PHASE4":1308,"NA":1310},{"trials":1297,"activeCount":99},[],{"trials":1299,"activeCount":99},[],{"trials":1301,"activeCount":99},[1302],{"nctId":1252,"briefTitle":1253,"status":282,"phases":1303,"primaryCompletion":1255,"completion":1256,"start":1045,"enrollment":1257,"conditions":1304,"interventions":1305},[89],[1259],[1243,1261,1262,1263,1264,1265,1266,1267,1268,1269],{"trials":1307,"activeCount":99},[],{"trials":1309,"activeCount":99},[],{"trials":1311,"activeCount":99},[],{"intervention":1263,"totalTrials":95,"cells":1313},{"EARLY_PHASE1":1314,"PHASE1":1316,"PHASE2":1318,"PHASE3":1324,"PHASE4":1326,"NA":1328},{"trials":1315,"activeCount":99},[],{"trials":1317,"activeCount":99},[],{"trials":1319,"activeCount":99},[1320],{"nctId":1252,"briefTitle":1253,"status":282,"phases":1321,"primaryCompletion":1255,"completion":1256,"start":1045,"enrollment":1257,"conditions":1322,"interventions":1323},[89],[1259],[1243,1261,1262,1263,1264,1265,1266,1267,1268,1269],{"trials":1325,"activeCount":99},[],{"trials":1327,"activeCount":99},[],{"trials":1329,"activeCount":99},[],{"intervention":1264,"totalTrials":95,"cells":1331},{"EARLY_PHASE1":1332,"PHASE1":1334,"PHASE2":1336,"PHASE3":1342,"PHASE4":1344,"NA":1346},{"trials":1333,"activeCount":99},[],{"trials":1335,"activeCount":99},[],{"trials":1337,"activeCount":99},[1338],{"nctId":1252,"briefTitle":1253,"status":282,"phases":1339,"primaryCompletion":1255,"completion":1256,"start":1045,"enrollment":1257,"conditions":1340,"interventions":1341},[89],[1259],[1243,1261,1262,1263,1264,1265,1266,1267,1268,1269],{"trials":1343,"activeCount":99},[],{"trials":1345,"activeCount":99},[],{"trials":1347,"activeCount":99},[],{"intervention":1265,"totalTrials":95,"cells":1349},{"EARLY_PHASE1":1350,"PHASE1":1352,"PHASE2":1354,"PHASE3":1360,"PHASE4":1362,"NA":1364},{"trials":1351,"activeCount":99},[],{"trials":1353,"activeCount":99},[],{"trials":1355,"activeCount":99},[1356],{"nctId":1252,"briefTitle":1253,"status":282,"phases":1357,"primaryCompletion":1255,"completion":1256,"start":1045,"enrollment":1257,"conditions":1358,"interventions":1359},[89],[1259],[1243,1261,1262,1263,1264,1265,1266,1267,1268,1269],{"trials":1361,"activeCount":99},[],{"trials":1363,"activeCount":99},[],{"trials":1365,"activeCount":99},[],{"intervention":1266,"totalTrials":95,"cells":1367},{"EARLY_PHASE1":1368,"PHASE1":1370,"PHASE2":1372,"PHASE3":1378,"PHASE4":1380,"NA":1382},{"trials":1369,"activeCount":99},[],{"trials":1371,"activeCount":99},[],{"trials":1373,"activeCount":99},[1374],{"nctId":1252,"briefTitle":1253,"status":282,"phases":1375,"primaryCompletion":1255,"completion":1256,"start":1045,"enrollment":1257,"conditions":1376,"interventions":1377},[89],[1259],[1243,1261,1262,1263,1264,1265,1266,1267,1268,1269],{"trials":1379,"activeCount":99},[],{"trials":1381,"activeCount":99},[],{"trials":1383,"activeCount":99},[],{"intervention":1267,"totalTrials":95,"cells":1385},{"EARLY_PHASE1":1386,"PHASE1":1388,"PHASE2":1390,"PHASE3":1396,"PHASE4":1398,"NA":1400},{"trials":1387,"activeCount":99},[],{"trials":1389,"activeCount":99},[],{"trials":1391,"activeCount":99},[1392],{"nctId":1252,"briefTitle":1253,"status":282,"phases":1393,"primaryCompletion":1255,"completion":1256,"start":1045,"enrollment":1257,"conditions":1394,"interventions":1395},[89],[1259],[1243,1261,1262,1263,1264,1265,1266,1267,1268,1269],{"trials":1397,"activeCount":99},[],{"trials":1399,"activeCount":99},[],{"trials":1401,"activeCount":99},[],{"intervention":1268,"totalTrials":95,"cells":1403},{"EARLY_PHASE1":1404,"PHASE1":1406,"PHASE2":1408,"PHASE3":1414,"PHASE4":1416,"NA":1418},{"trials":1405,"activeCount":99},[],{"trials":1407,"activeCount":99},[],{"trials":1409,"activeCount":99},[1410],{"nctId":1252,"briefTitle":1253,"status":282,"phases":1411,"primaryCompletion":1255,"completion":1256,"start":1045,"enrollment":1257,"conditions":1412,"interventions":1413},[89],[1259],[1243,1261,1262,1263,1264,1265,1266,1267,1268,1269],{"trials":1415,"activeCount":99},[],{"trials":1417,"activeCount":99},[],{"trials":1419,"activeCount":99},[],{"intervention":1269,"totalTrials":95,"cells":1421},{"EARLY_PHASE1":1422,"PHASE1":1424,"PHASE2":1426,"PHASE3":1432,"PHASE4":1434,"NA":1436},{"trials":1423,"activeCount":99},[],{"trials":1425,"activeCount":99},[],{"trials":1427,"activeCount":99},[1428],{"nctId":1252,"briefTitle":1253,"status":282,"phases":1429,"primaryCompletion":1255,"completion":1256,"start":1045,"enrollment":1257,"conditions":1430,"interventions":1431},[89],[1259],[1243,1261,1262,1263,1264,1265,1266,1267,1268,1269],{"trials":1433,"activeCount":99},[],{"trials":1435,"activeCount":99},[],{"trials":1437,"activeCount":99},[],{"intervention":1439,"totalTrials":95,"cells":1440},"Chemotherapy monitoring by circulating tumor DNA analysis",{"EARLY_PHASE1":1441,"PHASE1":1443,"PHASE2":1445,"PHASE3":1457,"PHASE4":1459,"NA":1461},{"trials":1442,"activeCount":99},[],{"trials":1444,"activeCount":99},[],{"trials":1446,"activeCount":99},[1447],{"nctId":1448,"briefTitle":1449,"status":945,"phases":1450,"primaryCompletion":1451,"completion":1451,"start":1452,"enrollment":1453,"conditions":1454,"interventions":1456},"NCT04720729","Chemotherapy Monitoring by ctDNA in HER2- Metastatic Breast Cancer",[89],"2025-04-21","2021-04-21",160,[1455],"HER2-negative Metastatic Breast Cancer",[1439],{"trials":1458,"activeCount":99},[],{"trials":1460,"activeCount":99},[],{"trials":1462,"activeCount":99},[],{"intervention":1464,"totalTrials":95,"cells":1465},"VDC-IE x2",{"EARLY_PHASE1":1466,"PHASE1":1468,"PHASE2":1470,"PHASE3":1485,"PHASE4":1487,"NA":1489},{"trials":1467,"activeCount":99},[],{"trials":1469,"activeCount":99},[],{"trials":1471,"activeCount":99},[1472],{"nctId":1473,"briefTitle":1474,"status":282,"phases":1475,"primaryCompletion":1476,"completion":1477,"start":1256,"enrollment":327,"conditions":1478,"interventions":1480},"NCT03011528","First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years (CombinaiR3)",[89],"2022-08","2023-11",[1479],"Ewing Sarcoma Family of Tumors",[1464,1481,1482,1483,1484],"VDC-IE","TEMIRI","Consolidation BuMel","Maintenance",{"trials":1486,"activeCount":99},[],{"trials":1488,"activeCount":99},[],{"trials":1490,"activeCount":99},[],{"intervention":1481,"totalTrials":95,"cells":1492},{"EARLY_PHASE1":1493,"PHASE1":1495,"PHASE2":1497,"PHASE3":1503,"PHASE4":1505,"NA":1507},{"trials":1494,"activeCount":99},[],{"trials":1496,"activeCount":99},[],{"trials":1498,"activeCount":99},[1499],{"nctId":1473,"briefTitle":1474,"status":282,"phases":1500,"primaryCompletion":1476,"completion":1477,"start":1256,"enrollment":327,"conditions":1501,"interventions":1502},[89],[1479],[1464,1481,1482,1483,1484],{"trials":1504,"activeCount":99},[],{"trials":1506,"activeCount":99},[],{"trials":1508,"activeCount":99},[],{"intervention":1482,"totalTrials":95,"cells":1510},{"EARLY_PHASE1":1511,"PHASE1":1513,"PHASE2":1515,"PHASE3":1521,"PHASE4":1523,"NA":1525},{"trials":1512,"activeCount":99},[],{"trials":1514,"activeCount":99},[],{"trials":1516,"activeCount":99},[1517],{"nctId":1473,"briefTitle":1474,"status":282,"phases":1518,"primaryCompletion":1476,"completion":1477,"start":1256,"enrollment":327,"conditions":1519,"interventions":1520},[89],[1479],[1464,1481,1482,1483,1484],{"trials":1522,"activeCount":99},[],{"trials":1524,"activeCount":99},[],{"trials":1526,"activeCount":99},[],{"intervention":1483,"totalTrials":95,"cells":1528},{"EARLY_PHASE1":1529,"PHASE1":1531,"PHASE2":1533,"PHASE3":1539,"PHASE4":1541,"NA":1543},{"trials":1530,"activeCount":99},[],{"trials":1532,"activeCount":99},[],{"trials":1534,"activeCount":99},[1535],{"nctId":1473,"briefTitle":1474,"status":282,"phases":1536,"primaryCompletion":1476,"completion":1477,"start":1256,"enrollment":327,"conditions":1537,"interventions":1538},[89],[1479],[1464,1481,1482,1483,1484],{"trials":1540,"activeCount":99},[],{"trials":1542,"activeCount":99},[],{"trials":1544,"activeCount":99},[],{"intervention":1484,"totalTrials":95,"cells":1546},{"EARLY_PHASE1":1547,"PHASE1":1549,"PHASE2":1551,"PHASE3":1557,"PHASE4":1559,"NA":1561},{"trials":1548,"activeCount":99},[],{"trials":1550,"activeCount":99},[],{"trials":1552,"activeCount":99},[1553],{"nctId":1473,"briefTitle":1474,"status":282,"phases":1554,"primaryCompletion":1476,"completion":1477,"start":1256,"enrollment":327,"conditions":1555,"interventions":1556},[89],[1479],[1464,1481,1482,1483,1484],{"trials":1558,"activeCount":99},[],{"trials":1560,"activeCount":99},[],{"trials":1562,"activeCount":99},[],{"intervention":1564,"totalTrials":95,"cells":1565},"PLX038",{"EARLY_PHASE1":1566,"PHASE1":1568,"PHASE2":1570,"PHASE3":1582,"PHASE4":1584,"NA":1586},{"trials":1567,"activeCount":99},[],{"trials":1569,"activeCount":99},[],{"trials":1571,"activeCount":99},[1572],{"nctId":1573,"briefTitle":1574,"status":945,"phases":1575,"primaryCompletion":1576,"completion":1576,"start":1577,"enrollment":1578,"conditions":1579,"interventions":1581},"NCT06162351","A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer",[89],"2025-05-15","2024-04-17",14,[1580,18],"Breast",[1564],{"trials":1583,"activeCount":99},[],{"trials":1585,"activeCount":99},[],{"trials":1587,"activeCount":99},[],{"intervention":1589,"totalTrials":95,"cells":1590},"AsiDNA",{"EARLY_PHASE1":1591,"PHASE1":1593,"PHASE2":1595,"PHASE3":1607,"PHASE4":1609,"NA":1611},{"trials":1592,"activeCount":99},[],{"trials":1594,"activeCount":99},[],{"trials":1596,"activeCount":99},[1597],{"nctId":1598,"briefTitle":1599,"status":945,"phases":1600,"primaryCompletion":1601,"completion":1601,"start":1602,"enrollment":1603,"conditions":1604,"interventions":1606},"NCT05394558","AsiDNA Children, Adolescents and Young Adults",[88,89],"2023-09-20","2022-05-27",8,[1605],"Recurrent High-grade Glioma",[1589],{"trials":1608,"activeCount":99},[],{"trials":1610,"activeCount":99},[],{"trials":1612,"activeCount":99},[],{"intervention":1614,"totalTrials":95,"cells":1615},"Atezolizumab + RP1",{"EARLY_PHASE1":1616,"PHASE1":1618,"PHASE2":1620,"PHASE3":1631,"PHASE4":1633,"NA":1635},{"trials":1617,"activeCount":99},[],{"trials":1619,"activeCount":99},[],{"trials":1621,"activeCount":99},[1622],{"nctId":1623,"briefTitle":1624,"status":945,"phases":1625,"primaryCompletion":1626,"completion":1626,"start":1627,"enrollment":262,"conditions":1628,"interventions":1630},"NCT06067061","\"neoBREASTIM\": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer",[88,89],"2025-05-07","2024-04-05",[1629],"Triple Negative Breast Neoplasms",[1614],{"trials":1632,"activeCount":99},[],{"trials":1634,"activeCount":99},[],{"trials":1636,"activeCount":99},[],{"intervention":1052,"totalTrials":95,"cells":1638},{"EARLY_PHASE1":1639,"PHASE1":1641,"PHASE2":1643,"PHASE3":1649,"PHASE4":1651,"NA":1653},{"trials":1640,"activeCount":99},[],{"trials":1642,"activeCount":99},[],{"trials":1644,"activeCount":99},[1645],{"nctId":1042,"briefTitle":1043,"status":895,"phases":1646,"primaryCompletion":1045,"start":1046,"enrollment":670,"conditions":1647,"interventions":1648},[89],[1048],[1050,1051,1052],{"trials":1650,"activeCount":99},[],{"trials":1652,"activeCount":99},[],{"trials":1654,"activeCount":99},[],{"intervention":1089,"totalTrials":95,"cells":1656},{"EARLY_PHASE1":1657,"PHASE1":1659,"PHASE2":1661,"PHASE3":1667,"PHASE4":1669,"NA":1671},{"trials":1658,"activeCount":99},[],{"trials":1660,"activeCount":99},[],{"trials":1662,"activeCount":99},[1663],{"nctId":1080,"briefTitle":1081,"status":282,"phases":1664,"primaryCompletion":1083,"completion":1084,"start":1085,"enrollment":1086,"conditions":1665,"interventions":1666},[89],[24],[1089,1090],{"trials":1668,"activeCount":99},[],{"trials":1670,"activeCount":99},[],{"trials":1672,"activeCount":99},[],{"intervention":1674,"totalTrials":95,"cells":1675},"Milademetan",{"EARLY_PHASE1":1676,"PHASE1":1678,"PHASE2":1680,"PHASE3":1692,"PHASE4":1694,"NA":1696},{"trials":1677,"activeCount":99},[],{"trials":1679,"activeCount":99},[],{"trials":1681,"activeCount":99},[1682],{"nctId":1683,"briefTitle":1684,"status":945,"phases":1685,"primaryCompletion":1686,"completion":1687,"start":1688,"enrollment":95,"conditions":1689,"interventions":1691},"NCT05932667","Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer",[89],"2023-11-24","2023-11-30","2023-10-12",[1690],"Advanced or Metastatic Breast Cancer",[1674],{"trials":1693,"activeCount":99},[],{"trials":1695,"activeCount":99},[],{"trials":1697,"activeCount":99},[],{"intervention":1699,"totalTrials":95,"cells":1700},"Trastuzumab - Emtansine",{"EARLY_PHASE1":1701,"PHASE1":1703,"PHASE2":1705,"PHASE3":1718,"PHASE4":1720,"NA":1722},{"trials":1702,"activeCount":99},[],{"trials":1704,"activeCount":99},[],{"trials":1706,"activeCount":99},[1707],{"nctId":1708,"briefTitle":1709,"status":282,"phases":1710,"primaryCompletion":1711,"completion":1712,"start":1713,"enrollment":1714,"conditions":1715,"interventions":1717},"NCT01975142","Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.",[89],"2018-02-13","2019-01-21","2013-11-07",155,[1716],"Metastatic Breast Cancer, HER2 Negative Primary Tumor",[1699],{"trials":1719,"activeCount":99},[],{"trials":1721,"activeCount":99},[],{"trials":1723,"activeCount":99},[],{"intervention":1725,"totalTrials":95,"cells":1726},"PCD",{"EARLY_PHASE1":1727,"PHASE1":1729,"PHASE2":1731,"PHASE3":1744,"PHASE4":1746,"NA":1748},{"trials":1728,"activeCount":99},[],{"trials":1730,"activeCount":99},[],{"trials":1732,"activeCount":99},[1733],{"nctId":1734,"briefTitle":1735,"status":282,"phases":1736,"primaryCompletion":1737,"completion":1738,"start":1739,"enrollment":1111,"conditions":1740,"interventions":1743},"NCT02244125","A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse\u002FRefractory Multiple Myeloma Patients Who Were First Treated Within the IFM\u002FDFCI 2009 Trial (PCD)",[89],"2017-01","2023-05-29","2014-04-14",[1741,1742],"Multiple Myeloma","First Relapse",[1725],{"trials":1745,"activeCount":99},[],{"trials":1747,"activeCount":99},[],{"trials":1749,"activeCount":99},[],{"intervention":1751,"totalTrials":95,"cells":1752},"sunitinib malate",{"EARLY_PHASE1":1753,"PHASE1":1755,"PHASE2":1757,"PHASE3":1770,"PHASE4":1772,"NA":1774},{"trials":1754,"activeCount":99},[],{"trials":1756,"activeCount":99},[],{"trials":1758,"activeCount":99},[1759],{"nctId":1760,"briefTitle":1761,"status":282,"phases":1762,"primaryCompletion":1763,"start":1764,"enrollment":1765,"conditions":1766,"interventions":1769},"NCT00792025","Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer",[89],"2011-05","2008-12",80,[1767,1768],"Bladder Cancer","Transitional Cell Cancer of the Renal Pelvis and Ureter",[1751],{"trials":1771,"activeCount":99},[],{"trials":1773,"activeCount":99},[],{"trials":1775,"activeCount":99},[],{"intervention":332,"totalTrials":95,"cells":1777},{"EARLY_PHASE1":1778,"PHASE1":1780,"PHASE2":1782,"PHASE3":1788,"PHASE4":1790,"NA":1792},{"trials":1779,"activeCount":99},[],{"trials":1781,"activeCount":99},[],{"trials":1783,"activeCount":99},[1784],{"nctId":322,"briefTitle":323,"status":282,"phases":1785,"primaryCompletion":325,"completion":325,"start":326,"enrollment":327,"conditions":1786,"interventions":1787},[89],[329,330],[299,332],{"trials":1789,"activeCount":99},[],{"trials":1791,"activeCount":99},[],{"trials":1793,"activeCount":99},[],{"intervention":1795,"totalTrials":95,"cells":1796},"Olaparib",{"EARLY_PHASE1":1797,"PHASE1":1799,"PHASE2":1814,"PHASE3":1816,"PHASE4":1818,"NA":1820},{"trials":1798,"activeCount":99},[],{"trials":1800,"activeCount":99},[1801],{"nctId":1802,"briefTitle":1803,"status":282,"phases":1804,"primaryCompletion":1805,"completion":1806,"start":1807,"enrollment":1808,"conditions":1809,"interventions":1813},"NCT03109080","Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)",[88],"2020-02-17","2021-11-29","2017-07-24",24,[1810,1811,1812],"Breast Neoplasms, Triple-Negative","Breast Neoplasm Malignant Female","Radiotherapy Side Effect",[1795],{"trials":1815,"activeCount":99},[],{"trials":1817,"activeCount":99},[],{"trials":1819,"activeCount":99},[],{"trials":1821,"activeCount":99},[],{"intervention":1823,"totalTrials":95,"cells":1824},"PLX038 + Tuvusertib",{"EARLY_PHASE1":1825,"PHASE1":1827,"PHASE2":1838,"PHASE3":1840,"PHASE4":1842,"NA":1844},{"trials":1826,"activeCount":99},[],{"trials":1828,"activeCount":99},[1829],{"nctId":1830,"briefTitle":1831,"status":945,"phases":1832,"primaryCompletion":1833,"completion":1833,"start":1834,"enrollment":1141,"conditions":1835,"interventions":1837},"NCT06337630","A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors",[88],"2025-11-24","2025-01-20",[1836],"Solid Tumor",[1823],{"trials":1839,"activeCount":99},[],{"trials":1841,"activeCount":99},[],{"trials":1843,"activeCount":99},[],{"trials":1845,"activeCount":99},[],{"intervention":1847,"totalTrials":25,"cells":1848},"Blood sampling",{"EARLY_PHASE1":1849,"PHASE1":1851,"PHASE2":1853,"PHASE3":1855,"PHASE4":1868,"NA":1870},{"trials":1850,"activeCount":99},[],{"trials":1852,"activeCount":99},[],{"trials":1854,"activeCount":99},[],{"trials":1856,"activeCount":99},[1857],{"nctId":1858,"briefTitle":1859,"status":282,"phases":1860,"primaryCompletion":1861,"completion":1862,"start":1863,"enrollment":1864,"conditions":1865,"interventions":1867},"NCT01349842","Circulating Tumor Cells to Guide Chemotherapy for Metastatic Breast Cancer",[90],"2016-01","2018-11-06","2010-03-02",265,[1866],"Breast Cancer Ductal Infiltrating Metastatic",[1847],{"trials":1869,"activeCount":99},[],{"trials":1871,"activeCount":99},[1872,1881,1890,1899],{"nctId":1873,"briefTitle":1874,"status":282,"phases":1875,"primaryCompletion":508,"completion":1876,"start":1877,"enrollment":8,"conditions":1878,"interventions":1880},"NCT01334008","Study of Circulating Tumoral DNA in Metastatic Choroidal Melanoma",[92],"2012-05","2011-04",[1879],"Choroidal Melanoma, Diffuse",[1847],{"nctId":1882,"briefTitle":1883,"status":282,"phases":1884,"primaryCompletion":1885,"completion":1885,"start":1886,"enrollment":1887,"conditions":1888,"interventions":1889},"NCT02849145","Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)",[92],"2020-02-25","2014-09",60,[21],[1847],{"nctId":1891,"briefTitle":1892,"status":282,"phases":1893,"primaryCompletion":1894,"completion":1894,"start":1895,"enrollment":898,"conditions":1896,"interventions":1898},"NCT02875652","Circulating Tumoral DNA in Choroidal Melanoma (ctDNA MU)",[92],"2019-04-02","2013-03-21",[1897],"Choroidal Melanoma",[1847],{"nctId":1900,"briefTitle":1901,"status":282,"phases":1902,"primaryCompletion":1903,"completion":1904,"start":1905,"enrollment":1906,"conditions":1907,"interventions":1908},"NCT02866149","Analysis of Circulating Tumor Markers in the Blood (ALCINA)",[92],"2024-07","2024-09","2015-07",682,[18],[1847],{"intervention":1910,"totalTrials":95,"cells":1911},"1 clinical examination of the wound, 1 sample taken with the curette, 1 sample by swabbing",{"EARLY_PHASE1":1912,"PHASE1":1914,"PHASE2":1916,"PHASE3":1918,"PHASE4":1920,"NA":1922},{"trials":1913,"activeCount":99},[],{"trials":1915,"activeCount":99},[],{"trials":1917,"activeCount":99},[],{"trials":1919,"activeCount":99},[],{"trials":1921,"activeCount":99},[],{"trials":1923,"activeCount":99},[1924],{"nctId":1925,"briefTitle":1926,"status":282,"phases":1927,"primaryCompletion":1928,"completion":1928,"start":1876,"enrollment":1929,"conditions":1930,"interventions":1931},"NCT02519166","Characterisation of Biofilm of the Chronic Wounds",[92],"2015-05",130,[952],[1910],{"intervention":1933,"totalTrials":95,"cells":1934},"Biopsy",{"EARLY_PHASE1":1935,"PHASE1":1937,"PHASE2":1939,"PHASE3":1941,"PHASE4":1943,"NA":1945},{"trials":1936,"activeCount":99},[],{"trials":1938,"activeCount":99},[],{"trials":1940,"activeCount":99},[],{"trials":1942,"activeCount":99},[],{"trials":1944,"activeCount":99},[],{"trials":1946,"activeCount":99},[1947],{"nctId":1948,"briefTitle":1949,"status":282,"phases":1950,"primaryCompletion":1951,"completion":1951,"start":1952,"enrollment":1169,"conditions":1953,"interventions":1954},"NCT02834494","Assessment of Response to Neo-adjuvant Chemotherapy for Patients With a Locally Advanced Breast Cancer With 3D Elastography (Shear Wave), NEOELASTO",[92],"2020-09-09","2016-02-22",[772],[1933],{"intervention":1956,"totalTrials":95,"cells":1957},"gene expression analysis",{"EARLY_PHASE1":1958,"PHASE1":1960,"PHASE2":1962,"PHASE3":1964,"PHASE4":1966,"NA":1968},{"trials":1959,"activeCount":99},[],{"trials":1961,"activeCount":99},[],{"trials":1963,"activeCount":99},[],{"trials":1965,"activeCount":99},[],{"trials":1967,"activeCount":99},[],{"trials":1969,"activeCount":99},[1970],{"nctId":1971,"briefTitle":1972,"status":282,"phases":1973,"primaryCompletion":1763,"start":1110,"enrollment":1974,"conditions":1975,"interventions":1976},"NCT00897624","Bone Marrow and Blood Samples From Patients With Metastatic Choroid Melanoma",[],15,[1048],[1956,1977],"reverse transcriptase-polymerase chain reaction",{"intervention":1977,"totalTrials":95,"cells":1979},{"EARLY_PHASE1":1980,"PHASE1":1982,"PHASE2":1984,"PHASE3":1986,"PHASE4":1988,"NA":1990},{"trials":1981,"activeCount":99},[],{"trials":1983,"activeCount":99},[],{"trials":1985,"activeCount":99},[],{"trials":1987,"activeCount":99},[],{"trials":1989,"activeCount":99},[],{"trials":1991,"activeCount":99},[1992],{"nctId":1971,"briefTitle":1972,"status":282,"phases":1993,"primaryCompletion":1763,"start":1110,"enrollment":1974,"conditions":1994,"interventions":1995},[],[1048],[1956,1977],{"intervention":1997,"totalTrials":95,"cells":1998},"BRIDGES gene panel testing",{"EARLY_PHASE1":1999,"PHASE1":2001,"PHASE2":2003,"PHASE3":2005,"PHASE4":2007,"NA":2009},{"trials":2000,"activeCount":99},[],{"trials":2002,"activeCount":99},[],{"trials":2004,"activeCount":99},[],{"trials":2006,"activeCount":99},[],{"trials":2008,"activeCount":99},[],{"trials":2010,"activeCount":99},[2011],{"nctId":2012,"briefTitle":2013,"status":282,"phases":2014,"primaryCompletion":2015,"completion":2016,"start":2017,"enrollment":2018,"conditions":2019,"interventions":2021},"NCT04145817","Breast Cancer Risk After Diagnostic Gene Sequencing",[92],"2021-08-27","2022-03-03","2019-10-22",405,[2020],"Genetic Predisposition to Disease",[1997,2022],"Breast cancer risk polygenic risk score",{"intervention":2022,"totalTrials":95,"cells":2024},{"EARLY_PHASE1":2025,"PHASE1":2027,"PHASE2":2029,"PHASE3":2031,"PHASE4":2033,"NA":2035},{"trials":2026,"activeCount":99},[],{"trials":2028,"activeCount":99},[],{"trials":2030,"activeCount":99},[],{"trials":2032,"activeCount":99},[],{"trials":2034,"activeCount":99},[],{"trials":2036,"activeCount":99},[2037],{"nctId":2012,"briefTitle":2013,"status":282,"phases":2038,"primaryCompletion":2015,"completion":2016,"start":2017,"enrollment":2018,"conditions":2039,"interventions":2040},[92],[2020],[1997,2022],{"intervention":2042,"totalTrials":95,"cells":2043},"Tumoral specific genetic alterations",{"EARLY_PHASE1":2044,"PHASE1":2046,"PHASE2":2048,"PHASE3":2050,"PHASE4":2052,"NA":2054},{"trials":2045,"activeCount":99},[],{"trials":2047,"activeCount":99},[],{"trials":2049,"activeCount":99},[],{"trials":2051,"activeCount":99},[],{"trials":2053,"activeCount":99},[],{"trials":2055,"activeCount":99},[2056],{"nctId":2057,"briefTitle":2058,"status":282,"phases":2059,"primaryCompletion":2060,"completion":2060,"start":1886,"enrollment":11,"conditions":2061,"interventions":2063},"NCT02546453","Use of Specific Genetic Alteration s of Tumoral Cells Identified by the Next Generation Sequencing Techniques (NGS) to Follow Peripheral Samples of Children With Metastatic and\u002For High Risk Solid Tumor - NGSKids",[92],"2021-01",[2062],"Metastatic and\u002For High Risk Solid Tumor of Children",[2042,2042],{"intervention":2065,"totalTrials":95,"cells":2066},"morphine chlorhydrate in intrasite gel",{"EARLY_PHASE1":2067,"PHASE1":2069,"PHASE2":2071,"PHASE3":2073,"PHASE4":2075,"NA":2077},{"trials":2068,"activeCount":99},[],{"trials":2070,"activeCount":99},[],{"trials":2072,"activeCount":99},[],{"trials":2074,"activeCount":99},[],{"trials":2076,"activeCount":99},[],{"trials":2078,"activeCount":99},[2079],{"nctId":2080,"briefTitle":2081,"status":282,"phases":2082,"primaryCompletion":2083,"completion":2083,"start":2084,"enrollment":2085,"conditions":2086,"interventions":2088},"NCT07207889","Retrospective Analysis of the Efficacy of Morphine Gel to Treat Pain Associated With Perineal RadioDermatitis",[],"2024-12-31","2024-12-01",17,[2087],"Dermatitis, Radiation Induced",[2065],{"intervention":2090,"totalTrials":95,"cells":2091},"fluorescence in situ hybridization",{"EARLY_PHASE1":2092,"PHASE1":2094,"PHASE2":2096,"PHASE3":2098,"PHASE4":2100,"NA":2102},{"trials":2093,"activeCount":99},[],{"trials":2095,"activeCount":99},[],{"trials":2097,"activeCount":99},[],{"trials":2099,"activeCount":99},[],{"trials":2101,"activeCount":99},[],{"trials":2103,"activeCount":99},[2104],{"nctId":2105,"briefTitle":2106,"status":282,"phases":2107,"primaryCompletion":2108,"start":2109,"enrollment":2110,"conditions":2111,"interventions":2112},"NCT00898014","Blood Levels of Tumor Cells in Predicting Response in Patients Receiving First-Line Chemotherapy for Stage IV Breast Cancer",[],"2010-04","2007-05",216,[15],[2090]]